Cefiderocol: new treatment option for Hospital-Acquired, ventilator associated pneumonia
Written By : Dr. Nandita Mohan
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2020-10-02 12:30 GMT | Update On 2020-10-03 06:36 GMT
Laboratory researcher, concept photo (stock image).
Credit: © tilialucida / stock.adobe.com
Advertisement
The U.S. Food and Drug Administration (FDA) has approved FETROJA® (cefiderocol) as a supplemental New Drug Application for the treatment of patients 18 years of age or older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the various susceptible Gram-negative microorganisms.
Cefiderocol is a cephalosporin antibiotic with a novel mechanism of penetrating the tough outer membrane of gram-negative bacteria with and the ability to overcome resistance mechanisms used by gram-negative pathogens to evade antibiotics.
The antibiotic was initially approved for the treatment of complicated urinary tract infections. However, it has now become the first approved antibiotic that functions as a siderophore and has a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens including carbapenem-resistant strains.
"Antimicrobial resistance is a major global health concern, and there is a clear need for new treatments such as FETROJA to give clinicians more options to fight life-threatening infections caused by Gram-negative pathogens," said Akira Kato, Ph.D., president, and CEO at Shionogi Inc. "This milestone represents Shionogi's long-standing and unwavering commitment to constantly fight evolving infectious diseases in an era realizing significant unmet needs", he further adds.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.